Navigation Links
Cardio fitness levels of breast cancer patients may affect survival
Date:5/23/2012

DURHAM, N.C. Women receiving care for breast cancer have significantly impaired cardio-pulmonary function that can persist for years after they have completed treatment, according to a study led by scientists at Duke University Medical Center.

The findings, reported online in the Journal of Clinical Oncology, also provide initial evidence that poor cardio-pulmonary function may be a strong predictor of survival among women with advanced breast cancer.

"We know that exercise tolerance tests, which measure cardiopulmonary function, are among some of the most important indicators of health and longevity in people who do not have cancer; however, relatively little research has been done assessing the clinical importance of these tests in patients with cancer," said Lee Jones, PhD, associate professor at Duke and lead author of the study. "Our work provides initial insights into the effects a cancer diagnosis and subsequent therapy may have on how the heart, lungs and rest of the body work together during exercise."

Treatment regimens for breast cancer have saved lives, contributing to a decline in death rates of about 2.2 percent a year since 1990. But successful treatments often come at a heavy price to the cardiopulmonary system, including the lungs, heart, blood, and skeletal muscle.

Certain types of chemotherapy can impair the heart's pumping function, reduce the ability of red blood cells to carry oxygen throughout the body, and diminish the ability of muscle cells to work efficiently. Patients may also experience secondary effects of therapy, becoming less active and gaining weight, which can also impair cardiopulmonary function.

To begin to understand the direct and indirect effects of therapy on breast cancer patients, Jones and his colleagues examined cardiopulmonary function at rest and during exercise in 248 women in various stages of treatment for breast cancer. All completed a carefully controlled cardio-pulmonary exercise test on a stationary bike, which escalated until the patients reached maximum exertion. At that point, the researchers took a measurement called VO2-peak, the gold standard assessment of cardiopulmonary function that athletes use to measure fitness levels and design training programs.

The researchers found that women with breast cancer, regardless of treatment status, had significantly worse cardio-pulmonary function than healthy women of the same age who were sedentary. Even among patients who had completed cancer therapy years previously, cardiopulmonary function levels were markedly impaired, suggesting that fitness levels may not recover after therapy. More striking, approximately a third of women in the study had a cardiopulmonary function score below the threshold that suggests people can function independently do household tasks, walk up and down stairs, or walk a half mile.

Among the patients with advanced breast cancer, median survival was significantly longer for women with higher cardiopulmonary function. Median survival was 36 months in high-fitness patients vs. 16 months in the low-fitness patients.

"Fitness level may be an important biomarker of survival among cancer patients," Jones said. "But the beautiful thing about fitness is that we can improve it with exercise training. Although we currently do not know if improving fitness in cancer patients is associated with longer survival, our data provides initial evidence to pursue this question."

Jones said the findings of this study indicate that exercise may be a good intervention for cancer patients both during and after therapy. His team at Duke has several studies underway examining the effects of exercise training on women with breast cancer, plus patients with other cancers.


'/>"/>
Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related biology news :

1. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
2. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
3. Tax on salt could reduce cardiovascular disease deaths by 3 percent
4. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
5. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
6. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
7. Canadian Journal of Cardiology publishes new atrial fibrillation guidelines
8. Genetic regulation of metabolomic biomarkers - paths to cardiovascular diseases and type 2 diabetes
9. MU researchers find unique protein organization in arteries associated with cardiovascular disease
10. EAE/ASE 3D echocardiography image acquisition recommendations
11. Gladstone scientist receives American Heart Associations Katz prize for cardiovascular research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
(Date:3/23/2017)... In today,s pre-market research, Stock-Callers.com ... Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals ... and Regulus Therapeutics Inc. (NASDAQ: RGLS ). ... its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more ... ...
(Date:3/22/2017)... TARRYTOWN, N.Y. , March 22, 2017 Regeneron ... among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK ... in the U.K. Biobank resource. The initiative will enable researchers ... of new medicines for a wide range of serious and ... ...
(Date:3/22/2017)... COPENHAGEN, Denmark , March 22, 2017 /PRNewswire/ ... that utilizes its innovative TransCon technology to address ... announced financial results for the full year ended ... a significant year for our company as we ... become a leading, integrated rare disease company with ...
Breaking Biology Technology: